Peter Curtin

4.7k citations

35 papers · 2.6k indexed · 2 hit papers · h-index 15

Impact in

Hematology top 0.5%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 0.5%
- Mesenchymal stem cell research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in ⓘ

Hematology 21
- Acute Myeloid Leukemia Research 12
- Hematopoietic Stem Cell Transplantation 8
- Chronic Myeloid Leukemia Treatments 7
Genetics 10
- Chronic Lymphocytic Leukemia Research 6
- Animal Genetics and Reproduction 4
- Mesenchymal stem cell research 2

Co-authors: Ashima Madan (2 shared papers)Richard T. Maziarz (9 shared papers)Yuet Wai Kan (4 shared papers)Fausto R. Loberiza (1 shared paper)Omer N. Koç (1 shared paper)Andrea Bacigalupo (1 shared paper)Brenda Cooper (1 shared paper)Stanton L. Gerson (1 shared paper)
Journals: Biology of Blood and Marrow Transplantation (8 papers)Blood (7 papers)Proceedings of the National Academy of Sciences (3 papers)Journal of Clinical Investigation (2 papers)Leukemia Research (1 paper)
Partner nations: United States Italy Australia

In The Last Decade

Peter Curtin

34 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation 2012 · 423 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Biology of Blood and Marrow Transplantation
2005 Biology of Blood and Marrow Transplantation

Peers

Countries citing papers authored by Peter Curtin

Since Specialization

Citations

This map shows the geographic impact of Peter Curtin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Curtin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Curtin more than expected).

Fields of papers citing papers by Peter Curtin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Curtin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Curtin. The network helps show where Peter Curtin may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Curtin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Curtin Line = papers co-authored together Peter Curtin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients Biology of Blood and Marrow Transplantation ·Hillard M. Lazarus, Omer N. Koç, Steven M. Devine, Peter Curtin, Richard T. Maziarz, H. Kent Holland, Elizabeth J. Shpall, Philip L. McCarthy, K Atkinson, Brenda Cooper, Stanton L. Gerson, Mary J. Laughlin, Fausto R. Loberiza, Annemarie Moseley, Andrea Bacigalupo Hit paper breakdown →	2005	607
2	First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation Biology of Blood and Marrow Transplantation ·Paul J. Martin, J. Douglas Rizzo, John R. Wingard, Karen K. Ballen, Peter Curtin, Corey Cutler, Mark R. Litzow, Yago Nieto, Bipin N. Savani, Jeffrey Schriber, Paul Shaughnessy, Donna A. Wall, Paul A. Carpenter Hit paper breakdown →	2012	423
3	Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood ·Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah A. Thomas, Robert Knight, M. Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List	2007	308
4	Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics Blood ·Daniel J. DeAngelo, Richard M. Stone, Mark Heaney, Stephen D. Nimer, Ronald Paquette, Rebecca B. Klisovic, Michael A. Caligiuri, Michael R. Cooper, Jean-Michel Lecerf, Michael D. Karol, Shihong Sheng, Nicholas H. G. Holford, Peter Curtin, Brian Druker, Michael C. Heinrich	2006	216
5	Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide Blood ·Peter Westervelt, Randy A. Brown, Douglas R. Adkins, H. Jean Khoury, Peter Curtin, David D. Hurd, Selina M. Luger, Margaret Kindlen, Timothy J. Ley, John F. DiPersio	2001	190
6	Human beta-globin gene expression in transgenic mice is enhanced by a distant DNase I hypersensitive site. Proceedings of the National Academy of Sciences ·Peter Curtin, D-P Liu, W Liu, J. Chang, Yuet Wai Kan	1989	119
7	A 24-base-pair sequence 3' to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proceedings of the National Academy of Sciences ·Ashima Madan, Peter Curtin	1993	106
8	Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders Biology of Blood and Marrow Transplantation ·Ginna G. Laport, Brenda M. Sandmaier, Barry E. Storer, Bart L. Scott, Monic J. Stuart, Thoralf Lange, Michael B. Maris, Edward Agura, Thomas R. Chauncey, Ruby M. Wong, Stephen J. Forman, Finn Bo Petersen, James C. Wade, Elliot Epner, Benedetto Bruno, Wolfgang Bethge, Peter Curtin, David G. Maloney, Karl G. Blume, Rainer Storb	2008	97
9	A distant gene deletion affects beta-globin gene function in an atypical gamma delta beta-thalassemia. Journal of Clinical Investigation ·Peter Curtin, Mario Pirastu, Yuet Wai Kan, J A Gobert-Jones, A. D. Stephens, H. Lehmann	1985	94
10	Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin‐2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease The Journal of Infectious Diseases ·Sean Emery, William B. Capra, David A. Cooper, Ronald T. Mitsuyasu, Joseph A. Kovacs, Pamela Vig, Mary Smolskis, Louis D. Saravolatz, H. Clifford Lane, Gwen Fyfe, Peter Curtin, (unknown)	2000	86
11	Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571) Leukemia & lymphoma ·José F. Leis, Daniel E. Stepan, Peter Curtin, J. Ford, Bin Peng, Susan Schubach, Brian Druker, Richard T. Maziarz	2003	82
12	Dissection of the enhancer activity of beta-globin 5' DNase I-hypersensitive site 2 in transgenic mice. Proceedings of the National Academy of Sciences ·D Liu, Judy C. Chang, Paolo Moi, W Liu, Yuet Wai Kan, Peter Curtin	1992	79
13	Hypoxia-induced in vivo sickling of transgenic mouse red cells. Journal of Clinical Investigation ·Edward M. Rubin, H. Ewa Witkowska, Elizabeth A. Spangler, Peter Curtin, Bertram H. Lubin, Narla Mohandas, S Clift	1991	49
14	Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome Journal of Hematology & Oncology ·Azra Raza, Naomi Galili, Natalie S. Callander, Leonel Ochoa, Lawrence D. Piro, Peter D. Emanuel, Stephanie Williams, Howard A. Burris, Stefan Faderl, Zeev Estrov, Peter Curtin, Richard A. Larson, James Keck, Marsha Jones, Lisa Meng, Gail L. Brown	2009	49
15	A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT) Journal of Clinical Oncology ·Joseph Bubalo, José F. Leis, Peter Curtin, Richard T. Maziarz, T.J. Kovascovics, Gabrielle Meyers, Jeannine S. McCune, Myrna Y. Munar, Brandon Hayes‐Lattin, N. C. Hughes Jones	2007	15
16	Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring Frontiers in Pharmacology ·Guofang Shen, Kao Tang Ying Moua, Kathryn Perkins, Deron Johnson, Arthur Li, Peter Curtin, Wei Gao, Jeannine S. McCune	2023	11
17	Autocrine stimulation by erythropoietin in transgenic mice results in erythroid proliferation without neoplastic transformation☆☆Supported in part by National Institutes of Health Grants KO8 HL02966 (A.M.) and R29 DK44956 (P.T.C.) and by a Medical Research Foundation of Oregon grant (P.T.C.). Blood Cells Molecules and Diseases ·Ashima Madan, Ching‐Shwun Lin, Z Wang, Peter Curtin	2003	9
18	Comparison of Surgical Smoke Generated During Electrosurgery with Aerosolized Particulates from Ultrasonic and High-Speed Cutting Annals of Biomedical Engineering ·Vincent J. Casey, Cian Martin, Peter Curtin, Kevin Buckley, Laoise M. McNamara	2020	9
19	Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. PubMed ·José F. Leis, Steven L. Primack, Susan Schubach, Peter Curtin, Brian Druker, Richard T. Maziarz	2004	8
20	Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy Blood Advances ·Ibrahim Aldoss, Joo Y. Song, Peter Curtin, Stephen J. Forman	2020	8

About Peter Curtin

Peter Curtin is a scholar working on Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health and Oncology, having authored 35 papers that have together received 2.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (8 papers), Chronic Myeloid Leukemia Treatments (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Acute Lymphoblastic Leukemia research (5 papers), CRISPR and Genetic Engineering (5 papers), Animal Genetics and Reproduction (4 papers) and Mesenchymal stem cell research (2 papers). The work is most often cited by research in Hematology (1.4k citations), Genetics (1.1k citations), Transplantation (68 citations), Immunology (352 citations) and Virology (72 citations). Peter Curtin has collaborated with scholars based in United States, Italy and Australia. Frequent co-authors include Ashima Madan, Richard T. Maziarz, Yuet Wai Kan, Fausto R. Loberiza, Omer N. Koç, Andrea Bacigalupo, Brenda Cooper, Stanton L. Gerson, K Atkinson and Steven M. Devine. Their work appears in journals such as Biology of Blood and Marrow Transplantation, Blood, Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact